Gilead Sciences Inc. (GILD)
Symbol Info
Listed Symbol GILD
Name Gilead Sciences Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $2.28
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $22,127,000,000
Latest Fiscal EPS $4.18
Price Info
21 Day Moving Average $63.7652
21 Day EMA $64.084350
50 Day Moving Average $63.9388
50 Day EMA $64.209220
200 Day EMA $65.195010
200 Day Moving Average 64.672080
52 Week High $74.80
52 Week Low $60.32
52 Week Change $-9.203899
Alpha -0.012521
Beta 1.0978
Standard Deviation 0.068843
R2 0.299868
Periods 60
Share Information
10 Day Average Volume 5,439,448
20 Day Average Volume 5,833,431
30 Day Average Volume 6,025,073
50 Day Average Volume 5,844,008
Outstanding Shares 1,266,455,481
Float Shares 1,258,980,767
Percent Float 99.41%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 2,798
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 71,053,973
Institute Holdings Percent -
Institute Sold Previous 3 Months 111,892,324
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 5
Insider Holdings Percent 0.60%
Insider Sold Previous 3 Months 1
Insiders Shares Owned 7,474,714
Price Change
7 Day Price Change $0.9200020
7 Day Percent Change 1.44%
21 Day Price Change $2.0100021
21 Day Percent Change 3.20%
30 Day Price Change $-0.8099976
30 Day Percent Change -1.23%
Month To Date Price Change $1.5300
Month To Date Percent 2.41%
90 Day Price Change $-1.678032
90 Day Percent Change -2.52%
Quarter To Date $1.530003
Quarter To Date Percent 2.41%
180 Day Price Change $3.130917
180 Day Percent Change 5.07%
200 Day Price Change $0.255417
200 Day Percent Change 0.40%
Year To Date $4.111683
Year To Date Percent 6.76%
Profile
Description Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition boosted Gilead's exposure to cell therapy in oncology.
Details
Issue Type CS
Market Cap $82,205,625,272
Sec Type EQS
Auditor Ernst & Young LLP
Total Shares Outstanding 1,266,455,481
CEO Daniel O¿Day
Employees 11,000
Last Audit UQ
Classification
CIK 0000882095
Industry Drug Manufacturers
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 333 Lakeside Drive
Foster City, CA 94404
Website http://www.gilead.com
Facisimile +1 650 578-9264
Telephone +1 650 574-3000
Email investor_relations@gilead.com
Key Ratios
Profitability
EBIT Margin 42.30
EBITDA Margin 48.7
Pre-Tax Profit Margin 53.9
Profit Margin Cont 22.95
Gross Margin 79.40
Profit Margin TOT 22.95
Income Statements
Revenue $16,761,000,000
Revenue Per Share $13.2346
Revenue 3 Years $-14.65
Revenue 5 Years $-4
Valuation Measures
PE Ratio 13.30
Enterprise Value $79,167,948,385
Price To Sales 4.904578
Price To Free Cash 26.100000
PE High Last 5 Years 64.2
Price To Book 3.5
Price To Cash Flow 9.7
PE Low Last 5 Years 5.9
Price To Tangible Book 23.3
Financial Strength
Total Debt To Equity 1.2
Int Coverage 9.3
Current Ratio 3.8
Leverage Ratio 2.9
Quick Ratio 3.4
Long Term Debt To Capital 0.52
Assets
Receivables Turnover 1.9
Invoice Turnover 5.40
Assets Turnover 0.10
Management Effectiveness
Return Assets 9.26
Return On Equity 26.89
Return On Capital 13.48
Dividends
Dividend 3 Years $9.14
Dividend 5 Years $-
Ex Dividend Date 2019-09-12 00:00:00.0
Dividend Rate $2.52
Dividend Yield 3.88%
Payment Type Cash


Your Recent History
NASDAQ
GILD
Gilead Sci..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.